SARS-CoV-2 (COVID-19)

"In December 2019, a new virus (initially called 'Novel Coronavirus 2019-nCoV' and later renamed to SARS-CoV-2) causing severe acute respiratory syndrome (coronavirus disease COVID-19) emerged in Wuhan, Hubei Province, China, and rapidly spread to other parts of China and other countries around the world, despite China's massive efforts to contain the disease within Hubei." [10.1186/s12942-020-00202-8]

"As with the original SARS-CoV epidemic of 2002/2003 and with seasonal influenza, geographic information systems and methods, including, among other application possibilities, online real-or near-real-time mapping of disease cases and of social media reactions to disease spread, predictive risk mapping using population travel data, and tracing and mapping super-spreader trajectories and contacts across space and time, are proving indispensable for timely and effective epidemic monitoring and response." [10.1186/s12942-020-00202-8]

"As with the original SARS-CoV epidemic of 2002/2003 [6] and with seasonal influenza [7], [8], geographic information systems (GIS) and methods, including, among other application possibilities, online real-or near-real-time mapping of disease cases and of social media reactions to disease spread, predictive risk mapping using population travel data, and tracing and mapping super-spreader trajectories and contacts across space and time (see, as an example, the first diagram in [9]), are proving indispensable for our timely understanding of the new disease source, dynamics and epidemiology, and in shaping our effective response to it." [10.1186/s12942-020-00202-8]

"This paper offers pointers to, and describes, a range of practical online/mobile GIS and mapping dashboards and applications for tracking the 2019/2020 coronavirus epidemic and associated events as they unfold around the world." [10.1186/s12942-020-00202-8]

"Some of these dashboards and applications are receiving data updates in near-real-time (at the time of writing), and one of them is meant for individual users (in China) to check if the app user has had any close contact with a person confirmed or suspected to have been infected with SARS-CoV-2 in the recent past." [10.1186/s12942-020-00202-8]

"An outbreak of clusters of viral pneumonia due to a novel coronavirus (2019-nCoV/SARS-CoV-2) happened in Wuhan, Hubei Province in China in December 2019." [10.1038/s41421-020-0148-0]

"Since the outbreak, several groups reported estimated R₀of Coronavirus Disease 2019 (COVID-19) and generated valuable prediction for the early phase of this outbreak." [10.1038/s41421-020-0148-0]

"After implementation of strict prevention and control measures in China, new estimation is needed." [10.1038/s41421-020-0148-0]

"An infectious disease dynamics SEIR (Susceptible, Exposed, Infectious, and Removed) model was applied to estimate the epidemic trend in Wuhan, China under two assumptions of R_t." [10.1038/s41421-020-0148-0]

"The estimated number of infections would continue to increase throughout February without any indication of dropping with R_t= 1.9, 2.6, or 3.1." [10.1038/s41421-020-0148-0]

"The number of infections would reach 11,044, 70,258, and 227,989, respectively, by 29 February 2020." [10.1038/s41421-020-0148-0]

"The number of infections in Wuhan, China reached 17,656-25,875 by the end of this phase with R₀as 3.1." [10.1038/s41421-020-0148-0]

"The number of infections was 32,061-46,905 by the end of this phase as R_tdecreased to 2.6." [10.1038/s41421-020-0148-0]

"The number of infections would reach 53,070-77,390 if R_tcould be reduced sequentially to 1.9." [10.1038/s41421-020-0148-0]

"The number of deaths in the current study was estimated based on previously reported CFRs." [10.1038/s41421-020-0148-0]

"The number of deaths estimated accordingly might be more close to the reality." [10.1038/s41421-020-0148-0]

"In the second assumption, R_twas assumed to gradually decrease at different phases from high level of transmission (R_t= 3.1, 2.6, and 1.9) to below 1 (R_t= 0.9 or 0.5) owing to increasingly implemented public health intervention." [10.1038/s41421-020-0148-0]

"The estimated number of infections would reach the peak in late February, which is 58,077-84,520 or 55,869-81,393." [10.1038/s41421-020-0148-0]

"Whether or not the peak of the number of infections would occur in February 2020 may be an important index for evaluating the sufficiency of the current measures taken in China." [10.1038/s41421-020-0148-0]

"Regardless of the occurrence of the peak, the currently strict measures in Wuhan should be continuously implemented and necessary strict public health measures should be applied in other locations in China with high number of COVID-19 cases, in order to reduce R_tto an ideal level and control the infection." [10.1038/s41421-020-0148-0]

"A new estimation of the epidemic dynamics taking the unprecedentedly strict prevention and control measures in China into consideration is required to better guide the future prevention decisions." [10.1038/s41421-020-0148-0]

"We hope to depict two types of epidemic dynamics to provide potential evaluation standard for the effects of current prevention and control measures, and to provide theoretical basis for future prevention decisions of the current epidemic in China." [10.1038/s41421-020-0148-0]

"SEIR model is a prediction model forecasting the number of infections in the future." [10.1038/s41421-020-0148-0]

"The data corresponding to actual situation in the future can not be determined and this makes model fitting almost impossible during the outbreak." [10.1038/s41421-020-0148-0]

"We would carry out model fitting according to the real data in pace with more information and knowledge about the characteristics of COVID-19 and the epidemics in the future." [10.1038/s41421-020-0148-0]

"Similar to outbreaks of many other infectious diseases, success in controlling the novel 2019 coronavirus infection requires a timely and accurate monitoring of the epidemic, particularly during its early period with rather limited data while the need for information increases explosively." [10.1186/s41256-020-00137-4]

"We used a second derivative model to characterize the coronavirus epidemic in China with cumulatively diagnosed cases during the first 2 months." [10.1186/s41256-020-00137-4]

"The analysis was further enhanced by an exponential model with a close-population assumption." [10.1186/s41256-020-00137-4]

"This model was built with the data and used to assess the detection rate during the study period, considering the differences between the true infections, detectable and detected cases." [10.1186/s41256-020-00137-4]

"Although it emerged gradually, the epidemic was highly responsive to massive interventions initiated on January 21, 2020, as indicated by results from both second derivative and exponential modeling analyses." [10.1186/s41256-020-00137-4]

"The epidemic started to decelerate immediately after the massive actions." [10.1186/s41256-020-00137-4]

"The results derived from our analysis signaled the decline of the epidemic 14 days before it eventually occurred on February 4, 2020." [10.1186/s41256-020-00137-4]

"The coronavirus epidemic appeared to be nonlinear and chaotic, and was responsive to effective interventions." [10.1186/s41256-020-00137-4]

"The methods used in this study can be applied in surveillance to inform and encourage the general public, public health professionals, clinicians and decision-makers to take coordinative and collaborative efforts to control the epidemic." [10.1186/s41256-020-00137-4]

"These data were used together with the data from the first source to monitor the dynamic of COVID-19 on a daily basis to 1) assess whether the COVID-19 epidemic was nonlinear and chaotic, 2) evaluate the responsiveness of the epidemic to the massive measures against it, and 3) inform the future trend of the epidemic." [10.1186/s41256-020-00137-4]

"These findings suggest the nonlinear and chaotic character of the COVID-19 outbreak." [10.1186/s41256-020-00137-4]

"The novel coronavirus (2019-nCoV, or COVID-19) epidemic first broke out in Wuhan and has been spreading in whole China and the world." [10.1186/s41256-020-00135-6]

"The numbers of new infections and deaths in Wuhan are still increasing, which have posed major public health and governance concerns." [10.1186/s41256-020-00135-6]

"A series of mandatory actions have been taken by the municipal and provincial governments supported by the central government, such as measures to restrict travels across cities, case detection and contact tracing, quarantine, guidance and information to the public, detection kit development, etc." [10.1186/s41256-020-00135-6]

"Challenges such as lacking effective drugs, insufficient hospital services and medical supplies, logistics, etc. have much alleviated with the solidarity of the whole society." [10.1186/s41256-020-00135-6]

"As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China." [10.1038/s41591-020-0822-7]

"Of these, 48,557 cases and 2,169 deaths occurred in the epicenter, Wuhan." [10.1038/s41591-020-0822-7]

"A key public health priority during the emergence of a novel pathogen is estimating clinical severity, which requires properly adjusting for the case ascertainment rate and the delay between symptoms onset and death." [10.1038/s41591-020-0822-7]

"Using public and published information, we estimate that the overall symptomatic case fatality risk (the probability of dying after developing symptoms) of COVID-19 in Wuhan was 1.4% (0.9-2.1%), which is substantially lower than both the corresponding crude or naïve confirmed case fatality risk (2,169 / 48,557 = 4.5%) and the approximator¹of deaths/deaths + recoveries (2,169 / 2,169 + 17,572 = 11%) as of 29 February 2020." [10.1038/s41591-020-0822-7]

"The risk of symptomatic infection increased with age (for example, at ~4% per year among adults aged 30-60 years)." [10.1038/s41591-020-0822-7]

"The virus responsible for COVID-19, SARS-CoV-2, is in the species SARS-like corona viruses." [10.1186/s12916-020-01533-w]

"At 125 nm, it is slightly larger than influenza, SARS and MERS viruses." [10.1186/s12916-020-01533-w]

"It is almost certainly a descendant from a bat corona virus of which there are many." [10.1186/s12916-020-01533-w]

"The closest is a virus that originated from the Rhinolophus bat which is > 96% homologous with the current SARS-CoV-2 virus." [10.1186/s12916-020-01533-w]

"Over the past few decades, disease outbreaks have become increasingly frequent and widespread." [10.1007/s40609-018-0123-y]

"The epicenters of these outbreaks have differed, and could be linked to different economic contexts." [10.1007/s40609-018-0123-y]

"The responses to these outbreaks have been “political” and inherently burdensome to marginalized populations." [10.1007/s40609-018-0123-y]

"Key lessons can be learned from exploring the narratives about the different epidemics in varying income settings." [10.1007/s40609-018-0123-y]

"Various themes of the politics of epidemics were prominent in the literature." [10.1007/s40609-018-0123-y]

"The narratives demonstrated the influence of power in whose narratives and what narratives are presented in the literature." [10.1007/s40609-018-0123-y]

"While marginalized populations were reported to have borne the brunt of all disease outbreaks in the different contexts, the prevalence of their narratives within the reviewed literature was limited." [10.1007/s40609-018-0123-y]

"The experiences and narratives of those most vulnerable to an epidemic-specifically poor communities-need to be represented in the literature." [10.1007/s40609-018-0123-y]

"This could contribute to mitigating some of the negative impact of the politics in epidemics." [10.1007/s40609-018-0123-y]

"For consistency, detailed discussions are limited to the findings that are directly related to the politics of epidemics, as defined in this paper." [10.1007/s40609-018-0123-y]

"The current outbreak of coronavirus disease 2019 (COVID-19) has prompted the World Health Organization (WHO) to declare a Public Health Emergency of International Concern on January 30, 2020." [10.1186/s12916-020-01551-8]

"As of February 28, 2020, COVID-19 has spread throughout China with nearly 80,000 confirmed cases and affected at least 51 countries and territories worldwide [43]." [10.1186/s12916-020-01551-8]

"Case isolation and contact tracing are common intervention used to control the outbreak of infectious diseases." [10.1186/s12916-020-01551-8]

"The Coronavirus Disease 2019 (COVID-19) outbreak has had alarming effects on human lives and the economies of affected countries." [10.1007/s41660-020-00113-y]

"With the world's manufacturing hubs experiencing a period of extended factory closures, the economic impact transcends territorial borders via global supply chains." [10.1007/s41660-020-00113-y]

"This paper provides a roadmap on how to evaluate the vulnerability that cascades through the supply chain due to a disease outbreak at the firm level, national level, and global scale." [10.1007/s41660-020-00113-y]

"The final extent of losses is not yet known, but the development of economic models combined with epidemiological models and network analysis techniques can yield more realistic estimates to select appropriate strategies in a timely manner." [10.1007/s41660-020-00113-y]

"In late 2019, a novel coronavirus was identified-2019-nCoV [34]." [10.1007/s10916-020-1536-6]

"This is likely the third time in three decades that a zoonotic coronavirus has jumped from infecting animals to humans [35]." [10.1007/s10916-020-1536-6]

"As of today, 213 have died and 9809 have been infected in China with the center of the outbreak being located in Wuhan but now having spread, with confirmed cases twenty-two other countries [36]." [10.1007/s10916-020-1536-6]

"While the fatality rate of 2019-nCoV is less than other recent respiratory virus outbreaks, it remains much higher than other commonly encountered causes of respiratory infection but its full impact is yet undetermined [37]." [10.1007/s10916-020-1536-6]

"SARS-CoV-2 is a new Coronavirus, with first infections detected in humans late in 2019." [10.1007/s15010-020-01409-4]

"The emergence of SARS-CoV-2 has led to a large outbreak in China and is currently causing outbreaks in many countries." [10.1007/s15010-020-01409-4]

"The disease spectrum ranges from uncomplicated upper respiratory tract infections to severe viral pneumonia with multiorgan failure and death." [10.1007/s15010-020-01409-4]

"It can be transmitted by droplets from asymptomatic or oligosymptomatic patients and possibly through aerosols in health care environments." [10.1007/s15010-020-01409-4]

"Outside China, we face enormous challenges: (1) to effectively contain the current and future outbreaks worldwide, and (2) to treat infected patients effectively and safely." [10.1007/s15010-020-01409-4]

"The novel coronavirus 2019-nCoV first appeared in December 2019 in Wuhan, China." [10.1007/s10729-020-09504-6]

"While most of the initial cases were linked to the Huanan Seafood Wholesale Market, person-to-person transmission has been verified." [10.1007/s10729-020-09504-6]

"A vaccine can not be developed and deployed for at least a year, preventing further transmission relies upon standard principles of containment, two of which are the isolation of known cases and the quarantine of persons believed at high risk of exposure." [10.1007/s10729-020-09504-6]

"This note presents probability models for assessing the effectiveness of case isolation and quarantine within a community during the initial phase of an outbreak with illustrations based on early observations from Wuhan." [10.1007/s10729-020-09504-6]

"The novel coronavirus (COVID-19) outbreak, which was identified in late 2019, requires special attention because of its future epidemics and possible global threats." [10.1007/s10916-020-01562-1]

"The novel coronavirus (COVID-19) is a global threat since it was identified in late 2019 [38]." [10.1007/s10916-020-01562-1]

"Beside clinical procedures and treatments, since Artificial Intelligence (AI) promises a new paradigm for healthcare, several different AI tools that are built upon Machine Learning (ML) algorithms are employed for analyzing data and decision-making processes." [10.1007/s10916-020-01562-1]

"This means that AI-driven tools help identify COVID-19 outbreaks as well as forecast their nature of spread across the globe." [10.1007/s10916-020-01562-1]

"Unlike other healthcare issues, for COVID-19, to detect COVID-19, AI-driven tools are expected to have active learning-based cross-population train/test models that employs multitudinal and multimodal data, which is the primary purpose of the paper." [10.1007/s10916-020-01562-1]

"The devastating case in Wuhan China and future epidemics require special attention [39], [40], [41]." [10.1007/s10916-020-01562-1]

"Considering the possible future epidemics of the COVID-19, in this paper, the importance of the AI-driven tools and their appropriate train and test models have been introduced and discussed." [10.1007/s10916-020-01562-1]

"Every year, during the Lunar New Year, the largest human migration in the world occurs in China." [10.1038/s41433-020-0790-7]

"Almost 3 billion passenger-journeys are made as travellers reunite with distant families [42]." [10.1038/s41433-020-0790-7]

"This year, things are different." [10.1038/s41433-020-0790-7]

"The recent emergence of a novel coronavirus (2019-nCoV), which caused an outbreak of viral pneumonia in Wuhan, China, has led to three Chinese cities; Wuhan, Huanggang, Ezhou, placed under lockdown to curb transmission." [10.1038/s41433-020-0790-7]

"Healthcare workers represented 20% of the infected [28]." [10.1038/s41433-020-0790-7]

"The 2019-nCoV serves as a reminder of the potential dangers posed by coronaviruses to both patients and doctors alike." [10.1038/s41433-020-0790-7]

"Government Department of Health and Social Care, London, UK." [10.1038/d41586-020-00457-y]

"Up to 31 January 2020, there have been 9811 officially reported confirmed cases of 2019-novel coronavirus (nCoV) infection in China since the epidemic began in December 2019 (updated data available at https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6)." [10.1007/s00134-020-05954-2]

"Coronavirus disease (COVID-19) has rapidly emerged as a global health threat." [10.1007/s00417-020-04641-8]

The purpose of this article is to share our local experience of stepping up infection control measures in ophthalmology to minimize COVID-19 infection of both healthcare workers and patients. [10.1007/s00417-020-04641-8]

"Infection control measures implemented in our ophthalmology clinic are discussed." [10.1007/s00417-020-04641-8]

"The measures are based on detailed risk assessment by both local ophthalmologists and infection control experts." [10.1007/s00417-020-04641-8]

"For administrative control, in order to lower patient attendance, text messages with an enquiry phone number were sent to patients to reschedule appointments or arrange drug refill." [10.1007/s00417-020-04641-8]

In order to minimize cross-infection of COVID-19, a triage system was set up to identify patients with fever, respiratory symptoms, acute conjunctivitis or recent travel to outbreak areas and to encourage these individuals to postpone their appointments for at least 14 days. [10.1007/s00417-020-04641-8]

"Micro-aerosol generating procedures, such as non-contact tonometry and operations under general anaesthesia were avoided." [10.1007/s00417-020-04641-8]

"All elective clinical services were suspended." [10.1007/s00417-020-04641-8]

"Infection control training was provided to all clinical staff." [10.1007/s00417-020-04641-8]

"For environmental control, to reduce droplet transmission of COVID-19, installation of protective shields on slit lamps, frequent disinfection of equipment, and provision of eye protection to staff were implemented." [10.1007/s00417-020-04641-8]

"Universal masking, hand hygiene, and appropriate use of personal protective equipment (PPE) were promoted." [10.1007/s00417-020-04641-8]

"We hope our initial experience in stepping up infection control measures for COVID-19 infection in ophthalmology can help ophthalmologists globally to prepare for the potential community outbreak or pandemic." [10.1007/s00417-020-04641-8]

In order to minimize transmission of COVID-19, ophthalmologists should work closely with local infection control teams to implement infection control measures that are appropriate for their own clinical settings. [10.1007/s00417-020-04641-8]

"Up to 07:58 February 6, 2020: there have been 28,060 confirmed cases of 2019-novel coronavirus (2019-nCoV) infection in China." [10.1007/s00134-020-05964-0]

"Since the outbreak of 2019-nCoV in Wuhan, China, now there are confirmed cases in multiple countries and there are many health care workers who have been infected while they were unprotected or improperly protected." [10.1007/s00134-020-05964-0]

"As the 2019-nCoV is highly contagious and the transmission dynamics is still not fully understood [44], in large hospitals, such as Sichuan provincial people's hospital which has more than 4000 beds and a large number of outpatient visits every day, it was necessary to establish a hospital-specific protocol to deal with the new coronavirus infection." [10.1007/s00134-020-05964-0]

"Beginning at early December 2019, there is an outbreak of a novel 2019-nCoV in Wuhan, China." [10.1186/s13054-020-2786-x]

"Public Health Emergency of International Concern (PHEIC) was declared on 30 January 2020, by the World Health Organization (WHO) Emergency Committee." [10.1186/s13054-020-2786-x]

"The 2019-nCoV pandemic could lead to an influx of critically ill into the already strained hospital systems in mainland China." [10.1186/s13054-020-2786-x]

"Dealing with the pandemic requires a robust hospital-and city-wide command and control structure that could make quick and informed decisions among Chinese hospitals." [10.1186/s13054-020-2786-x]

"The response should be flexible and adjustable according to the size of the population impacted." [10.1186/s13054-020-2786-x]

"On December 31, 2019, China reported cases of respiratory illness in humans appearing first in Wuhan, Hubei Province, that involved a novel coronavirus SARS-CoV-2 (aka 2019-nCoV)." [10.1007/s00134-020-05967-x]

"This new emergency is a zoonotic disease with unknown animal reservoir and with evidence of person-to-person transmission [46]." [10.1007/s00134-020-05967-x]

"The basic reproductive number of this infection is estimated to be 2.2 (95% CI, 1.4-3.9) [12]." [10.1007/s00134-020-05967-x]

"The original version of this article unfortunately contained a mistake." [10.1007/s00134-020-05955-1]

"In late December 2019, an outbreak of the 2019-novel coronavirus (COVID-19) caused a substantial public health crisis in Wuhan, China, and then expeditiously spread all over China [44], [47], [48]." [10.1186/s13054-020-2832-8]

"As of March 4, 2020, 80,409 cases of COVID-19 had been confirmed in mainland China [49]." [10.1186/s13054-020-2832-8]

"While in Heilongjiang province, which locates in northeastern China with 38.24 million residents and an area of 473,000 km², all of its 13 cities were affected, making it one of the most serious areas for the outbreak of COVID-19 in China." [10.1186/s13054-020-2832-8]

"Up to February 23, 2020, there were 480 confirmed cases of COVID-19; however, no newly diagnosed cases since then." [10.1186/s13054-020-2832-8]

"A series of protocols had been established since the first confirmed case emerged, and we herein summarize our experience from Heilongjiang province in dealing with COVID-19." [10.1186/s13054-020-2832-8]

"In late December 2019, a cluster of patients with pneumonia of unknown cause was reported to local healthcare authorities, while a novel coronavirus (SARS-CoV-2) was identified as the etiology [45], [44], [47]." [10.1007/s00134-020-05966-y]

"As of February 4, 2020, 20,471 confirmed cases, including 2788 severe cases and 425 deaths, were reported in China [50]." [10.1007/s00134-020-05966-y]

"Use techniques honed during the SARS, H1N1 and Ebola epidemics to separate sick and well, keep workers safe and prepare for the next outbreak, says Nahid Bhadelia "[10.1038/d41586-020-00354-4]

"Since December 2019, a severe acute respiratory infection (SARI) caused by 2019 novel coronavirus (SARS-CoV-2), began to spread from Wuhan to all of China [12], [44], and indeed the world." [10.1007/s00134-020-05979-7]

"As of Feb 10, 2020, there are more than 40,000 confirmed cases and > 1000 deaths in China." [10.1007/s00134-020-05979-7]

"A new coronavirus was discovered after a cluster of pneumonia cases emerged in Wuhan City, Hubei Province, China, in December 2019 [45], [44] and has since spread widely within China and to several countries." [10.1007/s00270-020-02440-6]

"The World Health Organisation (WHO) declared the epidemic a Public Health Emergency of International Concern on 30 Jan 2020 and advised all countries to be prepared." [10.1007/s00270-020-02440-6]

"Intensive care unit "[10.1186/s13054-020-2824-8]

"World leaders and international donors must strengthen the most vulnerable nations' health-care systems." [10.1038/d41586-020-00379-9]

"Brain Awareness Week is the global campaign to foster public enthusiasm and support for brain science." [10.1007/s10072-020-04338-0]

"Every March, “partners host imaginative activities in their communities that share the wonders of the brain and the impact brain science has on our everyday lives”." [10.1007/s10072-020-04338-0]

"In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named “2019 novel coronavirus (2019-nCoV) by the World Health Organization (WHO) on 12 January 2020." [10.1186/s40779-020-0233-6]

"In December 2019, the 2019 novel coronavirus (2019-nCoV) was discovered and identified in the viral pneumonia cases that occurred in Wuhan, Hubei Province, China; And then was named by the World Health Organization (WHO) on 12 January 2020." [10.1186/s40779-020-0233-6]

"For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual." [10.1186/s40779-020-0233-6]

"For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed." [10.1186/s40779-020-0233-6]

"We drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University." [10.1186/s40779-020-0233-6]

"We also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections." [10.1186/s40779-020-0233-6]

"As the 2019-nCoV is a newly identified pathogen responsible for the outbreak of the pandemic disease, there is no sufficient evidence to reveal the whole nature of this virus." [10.1186/s40779-020-0233-6]

"Since the outbreak of 2019 novel coronavirus infection (2019-nCoV) in Wuhan City, China, by January 30, 2020, a total of 9692 confirmed cases and 15,238 suspected cases have been reported around 31 provinces or cities in China." [10.1007/s12519-020-00343-7]

"Among the confirmed cases, 1527 were severe cases, 171 had recovered and been discharged at home, and 213 died." [10.1007/s12519-020-00343-7]

"Among these cases, a total of 28 children aged from 1 month to 17 years have been reported in China." [10.1007/s12519-020-00343-7]

"For standardizing prevention and management of 2019-nCoV infections in children, we called up an experts' committee to formulate this experts' consensus statement." [10.1007/s12519-020-00343-7]

"The present consensus statement summarizes current strategies on diagnosis, treatment, and prevention of 2019-nCoV infection in children." [10.1007/s12519-020-00343-7]

"The pneumonia caused by the 2019 novel coronavirus (SARS-CoV-2, also called 2019-nCoV) recently break out in Wuhan, China, and was named as COVID-19." [10.1007/s00259-020-04735-9]

"With the spread of the disease, similar cases have also been confirmed in other regions of China." [10.1007/s00259-020-04735-9]

"We aimed to report the imaging and clinical characteristics of these patients infected with SARS-CoV-2 in Guangzhou, China." [10.1007/s00259-020-04735-9]

"All patients with laboratory-identified SARS-CoV-2 infection by real-time polymerase chain reaction (PCR) were collected between January 23, 2020, and February 4, 2020, in a designated hospital (Guangzhou Eighth People's Hospital)." [10.1007/s00259-020-04735-9]

"All the included SARS-CoV-2-infected patients underwent non-contrast enhanced chest computed tomography (CT)." [10.1007/s00259-020-04735-9]

"We analyzed the clinical characteristics of the patients, as well as the distribution characteristics, pattern, morphology, and accompanying manifestations of lung lesions." [10.1007/s00259-020-04735-9]

"After 1-6 days (mean 3.5 days), follow-up chest CT images were evaluated to assess radiological evolution." [10.1007/s00259-020-04735-9]

"More than half of the patients presented bilateral, multifocal lung lesions, with peripheral distribution, and 53 (59%) patients had more than two lobes involved." [10.1007/s00259-020-04735-9]

"More than half of the patients presented bilateral, multifocal lung lesions, with peripheral distribution." [10.1007/s00259-020-04735-9]

"More than half of the patients had multilobar involvement and lesions were more frequent in the lower lobes." [10.1007/s00259-020-04735-9]

"Of all included patients, COVID-19 pneumonia presented with ground glass opacities in 65 (72%), consolidation in 12 (13%), crazy paving pattern in 11 (12%), interlobular thickening in 33 (37%), adjacent pleura thickening in 50 (56%), and linear opacities combined in 55 (61%)." [10.1007/s00259-020-04735-9]

"Pleural effusion, pericardial effusion, and lymphadenopathy were uncommon findings." [10.1007/s00259-020-04735-9]

"Pleural effusion, pericardial effusion, cavitation, thoracic lymphadenopathy, and pulmonary emphysema were uncommon imaging findings in these patients." [10.1007/s00259-020-04735-9]

"SARS-CoV-2 infection can be confirmed based on the patient's history, clinical manifestations, imaging characteristics, and laboratory tests." [10.1007/s00259-020-04735-9]

"Chest CT examination plays an important role in the initial diagnosis of the novel coronavirus pneumonia." [10.1007/s00259-020-04735-9]

"Multiple patchy ground glass opacities in bilateral multiple lobular with periphery distribution are typical chest CT imaging features of the COVID-19 pneumonia." [10.1007/s00259-020-04735-9]

"These findings indicate that some patients with SARS-CoV-2 infection are asymptomatic." [10.1007/s00259-020-04735-9]

"These findings indicated that the absence of clinical symptoms can not rule out the diagnosis of infection." [10.1007/s00259-020-04735-9]

"The imaging evaluation of disease progression is not complete, and we will collect more follow-up CT data to observe the evolution and outcome of the disease and provide more imaging information to be correlated with clinical findings." [10.1007/s00259-020-04735-9]

"In late December 2019, a cluster of cases with 2019 Novel Coronavirus pneumonia (SARS-CoV-2) in Wuhan, China, aroused worldwide concern." [10.1007/s11606-020-05762-w]

"Previous studies have reported epidemiological and clinical characteristics of coronavirus disease 2019 (COVID-19)." [10.1007/s11606-020-05762-w]

"The purpose of this brief review is to summarize those published studies as of late February 2020 on the clinical features, symptoms, complications, and treatments of COVID-19 and help provide guidance for frontline medical staff in the clinical management of this outbreak." [10.1007/s11606-020-05762-w]

"The viral pneumonia in Wuhan City, China has spread around China." [10.1007/s12519-020-00344-6]

"The virus has been proven to be a novel coronavirus (named as “2019-nCoV”) by World Health Organization (WHO)." [10.1007/s12519-020-00344-6]

"2019-nCoV belongs to beta-coronavirus genera." [10.1007/s12519-020-00344-6]

"On January 30, 2020, WHO re-evaluated the potential effects of 2019-nCoV infection in global public health, and declared this epidemic as a “Public Health Emergency of International Concern (PHEIC)." [10.1007/s12519-020-00344-6]

"An outbreak of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was first detected in Wuhan, Hubei, China." [10.1007/s12519-020-00354-4]

"People of all ages are susceptible to SARS-CoV-2 infection." [10.1007/s12519-020-00354-4]

"No information on severe pediatric patients with COVID-19 has been reported." [10.1007/s12519-020-00354-4]

"We aimed to describe the clinical features of severe pediatric patients with COVID-19." [10.1007/s12519-020-00354-4]

"We collected information including demographic data, symptoms, imaging data, laboratory findings, treatments and clinical outcomes of the patients with severe COVID-19." [10.1007/s12519-020-00354-4]

"The onset age of the eight patients ranged from 2 months to 15 years; six were boys." [10.1007/s12519-020-00354-4]

"The most common symptoms were polypnea (8/8), followed by fever (6/8) and cough (6/8)." [10.1007/s12519-020-00354-4]

"Laboratory findings revealed normal or increased whole blood counts (7/8), increased C-reactive protein, procalcitonin and lactate dehydrogenase (6/8), and abnormal liver function (4/8)." [10.1007/s12519-020-00354-4]

"Other findings included decreased CD16 + CD56 (4/8) and Th/Ts * (1/8), increased CD3 (2/8), CD4 (4/8) and CD8 (1/8), IL-6 (2/8), IL-10 (5/8) and IFN-γ (2/8)." [10.1007/s12519-020-00354-4]

"Treatment modalities were focused on symptomatic and respiratory support." [10.1007/s12519-020-00354-4]

"Up to February 24, 2020, three patients remained under treatment in ICU, the other five recovered and were discharged home." [10.1007/s12519-020-00354-4]

"Up to February 24, 2020, three patients remained in ICU (including two critically ill patients), the others recovered and were discharged without death." [10.1007/s12519-020-00354-4]

"In this series of severe pediatric patients in Wuhan, polypnea was the most common symptom, followed by fever and cough." [10.1007/s12519-020-00354-4]

"Common imaging changes included multiple patch-like shadows and ground-glass opacity; and a cytokine storm was found in these patients, which appeared more serious in critically ill patients." [10.1007/s12519-020-00354-4]

"For better understanding of the clinical features of severe pediatric patients with COVID-19 and for improving the diagnosis and treatment, we aimed to describe epidemiological and clinical features, imaging data, laboratory findings, clinical treatments and outcomes of severely or critically ill pediatric patients with COVID-19 in Wuhan City, China." [10.1007/s12519-020-00354-4]

"Demographic information and clinical characteristics including exposure history, anamnesis, signs and symptoms, chest computed tomographic (CT) scan or X-ray results, complications, treatments, clinical outcomes, and laboratory findings of each patient were obtained from the Electronic Medical Record System of Wuhan Children's Hospital." [10.1007/s12519-020-00354-4]

"The overall case fatality rate of severe pediatric patients is far lower than those of adults (49.0 %, 1023/2087) [6], which indicates a better clinical outcome in pediatric patients." [10.1007/s12519-020-00354-4]

"The purpose of this study was to observe the imaging characteristics of the novel coronavirus pneumonia." [10.1007/s00330-020-06731-x]

"The purpose of this study is to help early diagnosis based on imaging findings, and to participate in controlling the outbreak by effective countermeasures." [10.1007/s00330-020-06731-x]

"Sixty-three confirmed patients were enrolled from December 30, 2019 to January 31, 2020." [10.1007/s00330-020-06731-x]

"High-resolution CT (HRCT) of the chest was performed." [10.1007/s00330-020-06731-x]

"The number of affected lobes, ground glass nodules (GGO), patchy/punctate ground glass opacities, patchy consolidation, fibrous stripes and irregular solid nodules in each patient's chest CT image were recorded." [10.1007/s00330-020-06731-x]

"CT images of 63 confirmed patients were collected." [10.1007/s00330-020-06731-x]

"The mean age was 44.9 ± 15.2 years." [10.1007/s00330-020-06731-x]

"The mean number of affected lobes was 3.3 ± 1.8." [10.1007/s00330-020-06731-x]

"Fifty-four (85.7%) patients had patchy/punctate ground glass opacities, 14 (22.2%) patients had GGO, 12 (19.0%) patients had patchy consolidation, 11 (17.5%) patients had fibrous stripes and 8 (12.7%) patients had irregular solid nodules." [10.1007/s00330-020-06731-x]

"Fifty-four (85.7%) patients progressed, including single GGO increased, enlarged and consolidated; fibrous stripe enlarged, while solid nodules increased and enlarged." [10.1007/s00330-020-06731-x]

"Imaging changes in novel viral pneumonia are rapid." [10.1007/s00330-020-06731-x]

"Imaging changes of typical viral pneumonia and some specific imaging features were observed." [10.1007/s00330-020-06731-x]

"We need to strengthen the recognition of image changes to help clinicians to diagnose quickly and accurately." [10.1007/s00330-020-06731-x]

"• High-resolution CT (HRCT) of the chest is critical for early detection, evaluation of disease severity and follow-up of patients with the novel coronavirus pneumonia." [10.1007/s00330-020-06731-x]

"• Radiologists should be aware of the various features of the disease and temporal changes." [10.1007/s00330-020-06731-x]

"• Novel coronavirus (COVID-19)-infected pneumonia usually manifests as bilateral ground-glass opacities in the lung periphery on chest CT scans." [10.1007/s00330-020-06748-2]

"• Role of radiologists includes not only early detection of lung abnormality, but also suggestion of disease severity, potential progression to acute respiratory distress syndrome, and possible bacterial co-infection in hospitalized patients." [10.1007/s00330-020-06748-2]

"To assess the management and safety of epidural or general anesthesia for Cesarean delivery in parturients with coronavirus disease (COVID-19) and their newborns, and to evaluate the standardized procedures for protecting medical staff." [10.1007/s12630-020-01630-7]

"We retrospectively reviewed the cases of parturients diagnosed with severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection disease (COVID-19)." [10.1007/s12630-020-01630-7]

"Their epidemiologic history, chest computed tomography scans, laboratory measurements, and SARS-CoV-2 nucleic acid positivity were evaluated." [10.1007/s12630-020-01630-7]

"We also recorded the patients' demographic and clinical characteristics, anesthesia and surgery-related data, maternal and neonatal complications, as well as the health status of the involved medical staff." [10.1007/s12630-020-01630-7]

"All of the 17 patients underwent Cesarean delivery with anesthesia performed according to standardized anesthesia/surgery procedures." [10.1007/s12630-020-01630-7]

"Fourteen of the patients underwent continuous epidural anesthesia with 12 experiencing significant intraoperative hypotension." [10.1007/s12630-020-01630-7]

"Three patients received general anesthesia with tracheal intubation because emergency surgery was needed." [10.1007/s12630-020-01630-7]

"Three neonates were born prematurely." [10.1007/s12630-020-01630-7]

"There were no deaths or serious neonatal asphyxia events." [10.1007/s12630-020-01630-7]

"All neonatal SARS-CoV-2 nucleic acid tests were negative." [10.1007/s12630-020-01630-7]

"Both epidural and general anesthesia were safely used for Cesarean delivery in the parturients with COVID-19." [10.1007/s12630-020-01630-7]

"The incidence of hypotension during epidural anesthesia appeared excessive." [10.1007/s12630-020-01630-7]

"Proper patient transfer, medical staff access procedures, and effective biosafety precautions are important to protect medical staff from COVID-19." [10.1007/s12630-020-01630-7]

"Month, the outbreak of a new coronavirus from Wuhan, i.e., 2019-nCov, has spread rapidly across China and beyond, with an epidemiological link to the Huanan Seafood Wholesale Market, which sells live animals." [10.1007/s00330-020-06713-z]

"The number of people diagnosed with the virus has shown a sharp rise." [10.1007/s00330-020-06713-z]

"On January 30, 2020, China reported a total of 7,736 confirmed cases, 170 deaths, 9,267 suspected cases, and 124 discharged patients." [10.1007/s00330-020-06713-z]

"Chinese health authorities did an immediate investigation to characterize and control the disease, including isolation of people suspected to have the disease, close monitoring of contacts, epidemiological and clinical data collection from patients, and development of diagnostic and treatment procedures." [10.1007/s00330-020-06713-z]

"The genetic sequence of the 2019 novel coronavirus (2019-nCoV) enabled the rapid development of point-of-care real-time RT-PCR diagnostic tests specific for 2019-nCoV [36]." [10.1007/s00330-020-06713-z]

"The 2019-nCoV is a β CoV of group 2B with at least 70% similarity in genetic sequence to SARS-CoV [53]." [10.1007/s00330-020-06713-z]

"We report epidemiological and clinical investigations on ten pediatric SARS-CoV-2 infection cases confirmed by real-time reverse transcription PCR assay of SARS-CoV-2 RNA." [10.1038/s41591-020-0817-4]

"Symptoms in these cases were nonspecific and no children required respiratory support or intensive care." [10.1038/s41591-020-0817-4]

"Chest X-rays lacked definite signs of pneumonia, a defining feature of the infection in adult cases." [10.1038/s41591-020-0817-4]

"Eight children persistently tested positive on rectal swabs even after nasopharyngeal testing was negative, raising the possibility of fecal-oral transmission." [10.1038/s41591-020-0817-4]

"The aim of this case series is to illustrate the 18F-FDG PET/CT findings of patients with acute respiratory disease caused by COVID-19 in Wuhan, Hubei province of China." [10.1007/s00259-020-04734-w]

"We describe the 18F-FDG PET/CT results from four patients who were admitted to the hospital with respiratory symptoms and fever between January 13 and January 20, 2020, when the COVID-19 outbreak was still unrecognized and the virus infectivity was unknown." [10.1007/s00259-020-04734-w]

"A retrospective review of the patients' medical history, clinical and laboratory data, as well as imaging findings strongly suggested a diagnosis of COVID-19." [10.1007/s00259-020-04734-w]

"All patients had peripheral ground-glass opacities and/or lung consolidations in more than two pulmonary lobes." [10.1007/s00259-020-04734-w]

"Disseminated disease was absent, a finding suggesting that COVID-19 has pulmonary tropism." [10.1007/s00259-020-04734-w]

"Although 18F-FDG PET/CT can not be routinely used in an emergency setting and is generally not recommended for infectious diseases, our pilot data shed light on the potential clinical utility of this imaging technique in the differential diagnosis of complex cases." [10.1007/s00259-020-04734-w]

"We therefore describe for the first time the 18F-FDG PET/CT findings of four patients with COVID-19." [10.1007/s00259-020-04734-w]

"Although a bilateral involvement of the lung parenchyma can be observed in several benign and malignant lung diseases [54], tumors presenting as GGOs are unlikely to be FDG-avid [55]." [10.1007/s00259-020-04734-w]

"Although 18F-FDG PET/CT can not be routinely used in an emergency setting and is generally not recommended for infectious diseases, our current findings demonstrate that this imaging modality may play a complementary diagnostic role in COVID-19-especially at early stages when clinical symptoms are not specific and differential diagnosis is challenging." [10.1007/s00259-020-04734-w]

"High rates of false-negative findings may be explained by several reasons, including (1) the lack of SOPs for SARS-CoV-2 nucleic acid detection, differences in sample handling, storage, and processing, (2) disease stages and different viral loads according to anatomical site (e.g., alveoli versus upper respiratory tract), (3) the lack of independent validation of current testing, and (4) the potential high mutation rates of COVID-19." [10.1007/s00259-020-04734-w]

"Infection with COVID-19 is currently rare in children." [10.1007/s00247-020-04656-7]

"To describe chest CT findings in children with COVID-19." [10.1007/s00247-020-04656-7]

"We studied children at a large tertiary-care hospital in China, during the period from 28 January 2019 to 8 February 2020, who had positive reverse transcriptase polymerase chain reaction (RT-PCR) for COVID-19." [10.1007/s00247-020-04656-7]

"We recorded findings at any chest CT performed in the included children, along with core clinical observations." [10.1007/s00247-020-04656-7]

"All had had at least one CT scan after admission." [10.1007/s00247-020-04656-7]

"Three of these five had CT abnormality on the first CT scan (at 2 days, 4 days and 9 days, respectively, after onset of symptoms) in the form of patchy ground-glass opacities; all normalised during treatment." [10.1007/s00247-020-04656-7]

"Compared to reports in adults, we found similar but more modest lung abnormalities at CT in our small paediatric cohort." [10.1007/s00247-020-04656-7]

"We recorded the available clinical history, laboratory findings and any CT imaging in these children." [10.1007/s00247-020-04656-7]

"In December 2019, a novel coronavirus was first reported in Wuhan, China." [10.1038/s41423-020-0402-2]

"[33] It was named by the World Health Organization as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is responsible for coronavirus disease 2019 (COVID-19)." [10.1038/s41423-020-0402-2]

"Up to 28 February 2020, 79,394 cases have been confirmed according to China's National Health Commission." [10.1038/s41423-020-0402-2]

"Outside China, the virus has spread rapidly to over 36 countries and territories." [10.1038/s41423-020-0402-2]

"Knowledge of CT characteristics of COVID-19 pneumonia might be helpful to the early diagnosis and treatment of patients, and to control the spread of infection." [10.1007/s11604-020-00945-1]

"The chest CT images of the patient were collected to describe the CT manifestations and characteristics, and they were compared with the previous studies." [10.1007/s11604-020-00945-1]

"Multiple patchy ground-glass opacities (GGOs) were seen in bilateral lung, mostly in subpleural areas." [10.1007/s11604-020-00945-1]

"They progressed within 3 days, and nodular GGOs were also seen together with subpleural patchy GGOs." [10.1007/s11604-020-00945-1]

"These findings were consistent with the previous reports, and they might be useful for early detection and evaluation of severity of COVID-19 pneumonia." [10.1007/s11604-020-00945-1]

"The most severe sequelae after rehabilitation from SARS are femoral head necrosis and pulmonary fibrosis." [10.1038/s41413-020-0084-5]

"We performed a 15-year follow-up on the lung and bone conditions of SARS patients." [10.1038/s41413-020-0084-5]

"We evaluated the recovery from lung damage and femoral head necrosis in an observational cohort study of SARS patients using pulmonary CT scans, hip joint MRI examinations, pulmonary function tests and hip joint function questionnaires." [10.1038/s41413-020-0084-5]

"Eighty medical staff contracted SARS in 2003." [10.1038/s41413-020-0084-5]

"Seventy-one patients completed the 15-year follow-up." [10.1038/s41413-020-0084-5]

"The percentage of pulmonary lesions on CT scans diminished from 2003 (9.40 ± 7.83)% to 2004 (3.20 ± 4.78)% (P < 0.001) and remained stable thereafter until 2018 (4.60 ± 6.37) %." [10.1038/s41413-020-0084-5]

"Between 2006 and 2018, the proportion of patients with interstitial changes who had improved pulmonary function was lower than that of patients without lesions, as demonstrated by the one-second ratio (FEV₁/FVC%, t = 2.21, P = 0.04) and mid-flow of maximum expiration (FEF_25%–75%, t = 2.76, P = 0.01)." [10.1038/s41413-020-0084-5]

"Pulmonary interstitial damage and functional decline caused by SARS mostly recovered, with a greater extent of recovery within 2 years after rehabilitation." [10.1038/s41413-020-0084-5]

"Femoral head necrosis induced by large doses of steroid pulse therapy in SARS patients was not progressive and was partially reversible." [10.1038/s41413-020-0084-5]

"We used the two-sample t test or Satterthwaite t test to compare the lung function variables between patients who had abnormal CT and normal CT findings." [10.1038/s41413-020-0084-5]

"The pulmonary function test parameters were compared between the normal CT findings group (N = 22) and the abnormal CT findings group (N = 13)." [10.1038/s41413-020-0084-5]

"The pulmonary function of patients who had normal findings on CT after recovering from SARS in 2003 was substantially better than that of patients with abnormalities." [10.1038/s41413-020-0084-5]

"Femoral head necrosis also lessened to some extent, and correspondingly, the patients' hip joint function was generally stable over the past 15 years." [10.1038/s41413-020-0084-5]

"These findings have profound implications for physician understanding of clinical steroid therapy." [10.1038/s41413-020-0084-5]

"The novel contagious primary atypical pneumonia epidemic, which broke out in Wuhan, China, in December 2019, is now formally called Coronavirus Disease 2019 (COVID-19), with the causative virus named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)." [10.1038/s41423-020-0401-3]

"[56], [57] Recent studies have shown that in addition to dyspnea, hypoxemia, and acute respiratory distress, lymphopenia, and cytokine release syndrome are also important clinical features in patients with severe SARS-CoV-2 infection." [10.1038/s41423-020-0401-3]

"[35] This suggests that homeostasis of the immune system plays an important role in the development of COVID-19 pneumonia." [10.1038/s41423-020-0401-3]

"The 2019-nCoV epidemic has become a major challenging public health problem in China." [10.1007/s12519-020-00346-4]

"For standardizing the diagnosis and treatment strategies of 2019-nCoV pneumonia, National Health Commission of the People's Republic of China has released the Diagnosis and Treatment Standards of 2019-nCoV pneumonia, and updated the standards to the 4th edition based on the status of epidemic and accumulated experiences in clinical practice now [58]." [10.1007/s12519-020-00346-4]

"By the World Health Organization, a novel coronavirus (2019-nCoV) was identified as the causative virus of Wuhan pneumonia of unknown etiology by Chinese authorities on 7 January, 2020." [10.1186/s40249-020-00640-3]

"The virus was named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by International Committee on Taxonomy of Viruses on 11 February, 2020." [10.1186/s40249-020-00640-3]

"This study aimed to develop a mathematical model for calculating the transmissibility of the virus." [10.1186/s40249-020-00640-3]

"We developed a Bats-Hosts-Reservoir-People transmission network model for simulating the potential transmission from the infection source (probably be bats) to the human infection." [10.1186/s40249-020-00640-3]

"The next generation matrix approach was adopted to calculate the basic reproduction number (R₀) from the RP model to assess the transmissibility of the SARS-CoV-2." [10.1186/s40249-020-00640-3]

"The value of R₀was estimated of 2.30 from reservoir to person and 3.58 from person to person which means that the expected number of secondary infections that result from introducing a single infected individual into an otherwise susceptible population was 3.58." [10.1186/s40249-020-00640-3]

"Our model showed that the transmissibility of SARS-CoV-2 was higher than the Middle East respiratory syndrome in the Middle East countries, similar to severe acute respiratory syndrome, but lower than MERS in the Republic of Korea." [10.1186/s40249-020-00640-3]

"The genetic features and some clinical findings of the infection have been reported recently [35], [1], [33]." [10.1186/s40249-020-00640-3]

"A 75-year-old male who was confirmed as suffering of severe COVID pneumonia was transferred to the intensive care unit (ICU) of our hospital-a tertiary teaching hospital of a medical university." [10.1007/s00134-020-05976-w]

"He had a history of 10-year hypertension and one-year diabetes." [10.1007/s00134-020-05976-w]

"A physical examination unveiled that his body temperature was 35.5 ℃, his pulse was 54 beats per minute, his blood pressure was 136/79 mm Hg (noradrenaline 0.2 µg/kg/min), his oxygen saturation was 91% (noninvasive ventilation), and oxygenation index (OI: PO₂/FiO₂) 100 mmHg." [10.1007/s00134-020-05976-w]

"He was diagnosed with severe COVID-19 pneumonia combined with acute respiratory distress syndrome (ARDS), septic shock, and multiple organ dysfunction syndrome (MODS)." [10.1007/s00134-020-05976-w]

"In dynamic imaging, these white lines are clearly visible, which provides evidence for us to judge severe COVID-19 pneumonia." [10.1007/s00134-020-05976-w]

"We recently reported in Intensive Care Medicine the imaging changes of acute stage from a case of 75-year-old male patient with severe COVID-19 pneumonia combined acute respiratory distress syndrome (ARDS), septic shock, and multiple organ disfunction syndrome (MODS) who had a history of 10-year hypertension and 1-year diabetes." [10.1007/s00134-020-05990-y]

"He presently received advanced life support treatment including respiratory support (invasive mechanical ventilation) and circulatory support (vasoconstrictor assistance), as well as intermittent renal replacement therapy (IRRT) in intensive care unit (ICU) of our hospital-a tertiary teaching hospital of medical university." [10.1007/s00134-020-05990-y]

"Because his MODS still existed on the day 20 after symptom onset, we had to re-examine the chest computed tomographic (CT)." [10.1007/s00134-020-05990-y]

"The results showed that early changes of reticular pulmonary fibrosis appeared in Panels D, E, and F (marked by green arrows), compensatory emphysema occurred in Panels D and E (marked by blue arrows), and pulmonary cavity formation appeared in Panel F (marked by blue arrows), compared with acute stage of the day 5 after symptom onset, inflammatory lesions and ground glass shadow of Panels A and B (marked by red arrows), as well as septal line of Panel C (marked by yellow arrows)." [10.1007/s00134-020-05990-y]

"2019-nCoV is identified as the cause of an outbreak of viral pneumonia first detected in Wuhan, China and it continues to spread." [10.1007/s13238-020-00693-y]

"We summarized the characteristics of genes and receptors, antiviral therapy, and early warning and prediction." [10.1007/s13238-020-00693-y]

"We put forward the importance of vaccine development and recommend that relevant research be carried out in specific laboratories." [10.1007/s13238-020-00693-y]

"The emergence of 2019 novel coronavirus (2019-nCoV) is of global concern and might have emerged from RNA recombination among existing coronaviruses." [10.1007/s13337-020-00571-5]

"CoV spike (S) protein which is crucial for receptor binding, membrane fusion via conformational changes, internalization of the virus, host tissue tropism and comprises crucial targets for vaccine development, remain largely uncharacterized." [10.1007/s13337-020-00571-5]

"The present study has been planned to determine the sequence variation, structural and antigenic divergence of S glycoprotein which may be helpful for the management of 2019-nCoV infection." [10.1007/s13337-020-00571-5]

"The sequences of spike glycoprotein of 2019-nCoV and SARS coronavirus (SARS-CoV) were used for the comparison." [10.1007/s13337-020-00571-5]

"The variation in glycosylation sites was predicted by NetNGlyc 1.0 and validated by N-GlyDE server." [10.1007/s13337-020-00571-5]

"Antigenicity was predicted by NetCTL 1.2 and validated by IEDB Analysis Resource server." [10.1007/s13337-020-00571-5]

"Divergence was determined by using SuperPose Version 1.0 based on cryo-EM structure of the SARS coronavirus spike glycoprotein." [10.1007/s13337-020-00571-5]

"Addition of a novel glycosylation sites were observed in 2019-nCoV." [10.1007/s13337-020-00571-5]

"Antigenic analysis proposes that great antigenic differences exist between both the viral strains, but some of the epitopes were found to be similar between both the S proteins." [10.1007/s13337-020-00571-5]

"In spite of the variation in S protein amino acid composition, we found no significant difference in their structures." [10.1007/s13337-020-00571-5]

"Further, demonstration of novel Cytotoxic T lymphocyte epitopes may impart opportunities for the development of peptide based vaccine for the prevention of 2019-nCoV." [10.1007/s13337-020-00571-5]

"Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats^1–4." [10.1038/s41586-020-2012-7]

"Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans^5–7." [10.1038/s41586-020-2012-7]

"We report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China." [10.1038/s41586-020-2012-7]

"The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020." [10.1038/s41586-020-2012-7]

"The sequences are almost identical and share 79.6% sequence identity to SARS-CoV." [10.1038/s41586-020-2012-7]

"We show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus." [10.1038/s41586-020-2012-7]

"Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV." [10.1038/s41586-020-2012-7]

"We confirmed that 2019-nCoV uses the same cell entry receptor-angiotensin converting enzyme II (ACE2)-as SARS-CoV." [10.1038/s41586-020-2012-7]

"The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV)." [10.1038/s41423-020-0400-4]

"The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines." [10.1038/s41423-020-0400-4]

"We identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors." [10.1038/s41423-020-0400-4]

"SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells." [10.1038/s41423-020-0400-4]

"A novel infectious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China, in December 2019." [10.1007/s00134-020-05985-9]

"The disease (COVID-19) spread rapidly, reaching epidemic proportions in China, and has been found in 27 other countries." [10.1007/s00134-020-05985-9]

"As of February 27, 2020, over 82,000 cases of COVID-19 were reported, with > 2800 deaths." [10.1007/s00134-020-05985-9]

"No specific therapeutics are available, and current management includes travel restrictions, patient isolation, and supportive medical care." [10.1007/s00134-020-05985-9]

"This article will briefly review the rationale for angiotensin-converting enzyme 2 (ACE2) receptor as a specific target." [10.1007/s00134-020-05985-9]

"Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing global health emergency." [10.1186/s13578-020-00404-4]

"We highlight nine most important research questions concerning virus transmission, asymptomatic and presymptomatic virus shedding, diagnosis, treatment, vaccine development, origin of virus and viral pathogenesis." [10.1186/s13578-020-00404-4]

"Two recent studies provide initial insights into a novel coronavirus that is associated with an outbreak of human respiratory disease." [10.1038/s41579-020-0336-9]

"The outbreak of 2019-novel coronavirus disease (COVID-19) that is caused by SARS-CoV-2 has spread rapidly in China, and has developed to be a Public Health Emergency of International Concern." [10.1038/s41541-020-0170-0]

"No specific antiviral treatments or vaccines are available yet." [10.1038/s41541-020-0170-0]

"This work aims to share strategies and candidate antigens to develop safe and effective vaccines against SARS-CoV-2." [10.1038/s41541-020-0170-0]

"Therapeutic options in response to the 2019-nCoV outbreak are urgently needed." [10.1038/d41573-020-00016-0]

"We discuss the potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19), some of which are already moving into clinical trials." [10.1038/d41573-020-00016-0]

"Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health^1–3." [10.1038/s41586-020-2008-3]

"Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty." [10.1038/s41586-020-2008-3]

"A severe respiratory disease was recently reported in Wuhan, Hubei province, China." [10.1038/s41586-020-2008-3]

"As of 25 January 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 December 2019." [10.1038/s41586-020-2008-3]

"We study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 December 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough." [10.1038/s41586-020-2008-3]

"Metagenomic RNA sequencing⁴of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here 'WH-Human 1' coronavirus (and has also been referred to as '2019-nCoV')." [10.1038/s41586-020-2008-3]

"Phylogenetic analysis of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China⁵." [10.1038/s41586-020-2008-3]

"It has been reported that ACE2 is the main host cell receptor of 2019-nCoV and plays a crucial role in the entry of virus into the cell to cause the final infection." [10.1038/s41368-020-0074-x]

"To investigate the potential route of 2019-nCov infection on the mucosa of oral cavity, bulk RNA-seq profiles from two public databases including the Cancer Genome Atlas (TCGA) and Functional Annotation of the Mammalian Genome Cap Analysis of Gene Expression (FANTOM5 CAGE) dataset were collected." [10.1038/s41368-020-0074-x]

"To investigate the ACE2 expression on mucosa of oral cavity, we looked into the ACE2 expression in different oral sites." [10.1038/s41368-020-0074-x]

"RNA-seq profiling data of 13 organ types with para-carcinoma normal tissues from TCGA and 14 organ types with normal tissues from FANTOM5 CAGE were analyzed in order to explore and validate the expression of ACE2 on the mucosa of oral cavity." [10.1038/s41368-020-0074-x]

"Further, single-cell transcriptomes from an independent data generated in-house were used to identify and confirm the ACE2-expressing cell composition and proportion in oral cavity." [10.1038/s41368-020-0074-x]

"This receptor was highly enriched in epithelial cells of tongue." [10.1038/s41368-020-0074-x]

"Preliminarily, those findings have explained the basic mechanism that the oral cavity is a potentially high risk for 2019-nCoV infectious susceptibility and provided a piece of evidence for the future prevention strategy in dental clinical practice as well as daily life." [10.1038/s41368-020-0074-x]

"These findings suggest that the ACE2 plays an important role in cellular entry, thus ACE2-expressing cells may act as target cells and are susceptible to 2019-nCoV infection¹⁰." [10.1038/s41368-020-0074-x]

"These findings indicated that those organs with high ACE2-expressing cells should be considered as potential high risk for 2019-nCoV infection¹⁰." [10.1038/s41368-020-0074-x]

"Those preliminary findings have explained the basic mechanism that the oral cavity is a potentially high risk for 2019-nCoV infectious susceptibility and provide a piece of evidence for the future prevention strategy in clinical practice as well as daily life." [10.1038/s41368-020-0074-x]

"Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality." [10.1038/s41421-020-0153-3]

"There are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2." [10.1038/s41421-020-0153-3]

"Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery." [10.1038/s41421-020-0153-3]

"We present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network." [10.1038/s41421-020-0153-3]

"We present an integrative antiviral drug repurposing methodology, which combines a systems pharmacology-based network medicine platform that quantifies the interplay between the virus-host interactome and drug targets in the human PPI network." [10.1038/s41421-020-0153-3]

"The envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6 %, respectively, compared to SARS-CoV." [10.1038/s41421-020-0153-3]

"Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines." [10.1038/s41421-020-0153-3]

"We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the “Complementary Exposure” pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network." [10.1038/s41421-020-0153-3]

"The World Health Organization (WHO) has declared the novel coronavirus (2019-nCoV) outbreak a Public Health Emergency of International Concern (PHEIC),¹which is now formally named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)." [10.1038/s41423-020-0385-z]

"[132] As of 27 February 2020, a total of 82,178 cases of SARS-CoV-2 infection have been confirmed across the world, with 78,630 cases in China (https://ncov.dxy.cn/ncovh5/view/pneumonia?source=)." [10.1038/s41423-020-0385-z]

"The SARS-CoV-2 has been determined as the seventh member of the coronaviruses infected humans." [10.1038/s41423-020-0385-z]

"[133] Moreover, similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), the SARS-CoV-2 could also cause severe and fatal illness." [10.1038/s41423-020-0385-z]

"In late December 2019, a cluster of patients with 'atypical pneumonia' of unknown etiology was reported in Wuhan, China." [10.1038/s41591-020-0796-5]

"A novel human coronavirus, now provisionally called 'SARS-CoV-2', was identified as the cause of this disease, now named 'COVID-19'." [10.1038/s41591-020-0796-5]

"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system." [10.1038/s41569-020-0360-5]

"Particular attention should be given to cardiovascular protection during treatment for COVID-19." [10.1038/s41569-020-0360-5]

"A novel coronavirus, 2019-nCoV, emerged in Wuhan, China and then quickly spread worldwide, resulting in > 17,388 confirmed cases and 361 deaths as of 3 February 2020, thus calling for the development of safe and effective therapeutics and prophylatics." [10.1038/s41423-020-0374-2]

"[134], [135] "[10.1038/s41423-020-0374-2]

"The 2019-nCoV viral infection causes clusters of severe respiratory illness such as an acute respiratory distress syndrome (ARDS) similar to that caused by SARS-CoV (severe acute respiratory syndrome coronavirus) (Huang et al. [134])." [10.1007/s12250-020-00205-6]

"Both 2019-nCoV and SARS-CoV use the same receptor, ACE2 (angiotensin converting enzyme 2), to infect cells (Li et al. [30]; Zhou et al. [33])." [10.1007/s12250-020-00205-6]

"ACE2 is one of the central enzymes in the renin-angiotensin system (RAS) (Donoghue et al. [136]; Imai et al. [137]; Tipnis et al. [138]) that regulates blood pressure, fluid and electrolyte balance, and systemic vascular resistance (Paul et al. [139]; Zimmerman and Dunham [140])." [10.1007/s12250-020-00205-6]

"The novel coronavirus, 2019-nCov (named as SARS-CoV-2 by ICTV Coronaviridae Study Group on February 12, 2020), causes severe respiratory illness¹and has been spreading around the world rapidly." [10.1038/s41422-020-0290-0]

"[141] As of February 14, 2020, there are over 64,000 confirmed cases with 1,384 deaths." [10.1038/s41422-020-0290-0]

"This raises an urgent need for an effective treatment of the deadly disease." [10.1038/s41422-020-0290-0]

"Current antiviral drugs have limited effects on 2019-nCov (SARS-CoV-2)." [10.1038/s41422-020-0290-0]

"Our analysis of 2019-nCov (SARS-CoV-2) RNA genome from 19 patients in China, USA and Australia reveals that these viruses have differences in sequence (Fig.) "[10.1038/s41422-020-0290-0]

"These differences are mostly single nucleotide variations." [10.1038/s41422-020-0290-0]

"Fig." [10.1038/s41422-020-0290-0]

"Shows an example of single nucleotide variations that result in changes in amino acids 62 and 84 of ORF8 of 2019-nCov (SARS-CoV-2), a polypeptide implicated in driving coronavirus transition from bat to human." [10.1038/s41422-020-0290-0]

"This raises a serious challenge to the development of conventional drugs and of vaccines." [10.1038/s41422-020-0290-0]

"The same limitations apply to other deadly RNA viruses such as SARS or MERS." [10.1038/s41422-020-0290-0]

"Coronavirus disease (COVID-19), which appeared in December 2019, presents a global challenge, particularly in the rapid increase of critically ill patients with pneumonia and absence of definitive treatment." [10.1186/s13054-020-2818-6]

"Over 81,000 cases have been confirmed, with over 2700 deaths." [10.1186/s13054-020-2818-6]

"The mortality appears to be around 2%; early published data indicate 25.9% with SARS-CoV-2 pneumonia required ICU admission and 20.1% developed acute respiratory distress syndrome [142]." [10.1186/s13054-020-2818-6]

"After causing an initial cluster of Pneumonia in Wuhan City, Hubei Province, the 2019-nCoV has quickly spread through South East Asia and within a few weeks to Europe, Africa, and America." [10.1038/s41423-020-0377-z]

"Initial estimates suggested a mortality rate of 2% and that ~18% of the cases show severe symptoms, although such estimates are still subject to rapid changes (https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus(2019-ncov))." [10.1038/s41423-020-0377-z]

"[143], [144], [145] "[10.1038/s41423-020-0377-z]

"Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human infections and over 851 deaths in 27 countries since 2012." [10.1038/s41467-019-13940-6]

"There are no approved treatments for MERS-CoV infection although a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currently being evaluated in humans in the Kingdom of Saudi Arabia." [10.1038/s41467-019-13940-6]

"We show that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro." [10.1038/s41467-019-13940-6]

"We show that RDV provides superior antiviral activity against MERS-CoV in vitro and in vivo as compared with LPV/RTV-IFNb." [10.1038/s41467-019-13940-6]

"In mice, both prophylactic and therapeutic RDV improve pulmonary function and reduce lung viral loads and severe lung pathology." [10.1038/s41467-019-13940-6]

"Therapeutic LPV/RTV-IFNb improves pulmonary function but does not reduce virus replication or severe lung pathology." [10.1038/s41467-019-13940-6]

"We provide in vivo evidence of the potential for RDV to treat MERS-CoV infections." [10.1038/s41467-019-13940-6]

"Our studies were intended to generate the data required to justify further testing in nonhuman primates and collectively inform future human clinical trials." [10.1038/s41467-019-13940-6]

"With the ATS ALI and DAD histologic assessment tools described above, along with quantitation of cell death via cleaved caspase-3 antigen labeling, we show that only RDV therapy reduced ALI when initiated 1 dpi." [10.1038/s41467-019-13940-6]

"Bats are flying mammals distributed worldwide known to host several types of Coronavirus (CoV)." [10.1007/s00248-019-01391-x]

"Since they were reported as the probable source of spillover of highly pathogenic CoV into the human population, investigating the circulation of this virus in bats around the world became of great importance." [10.1007/s00248-019-01391-x]

"We analyzed samples from 103 bats from two distinct regions in Brazil." [10.1007/s00248-019-01391-x]

"Coronavirus from the Alphacoronavirus genus was detected in 12 animals, 11 from São José do Rio Preto-SP region and 1 from Barreiras-BA region, resulting in a prevalence of 17.18% and 2.56% respectively." [10.1007/s00248-019-01391-x]

"Phylogenetic analysis based on nsP12 genomic region suggests that the sequences group according to host family and sampling location." [10.1007/s00248-019-01391-x]

"Studies on the circulation of these viruses in bats remain important to understand the ecology and evolutionary relationship of these pathogens." [10.1007/s00248-019-01391-x]

"Our results indicate that despite the association between BtCoV and host family seen here, the close contact between animals from different families may result in virus transmission." [10.1007/s00248-019-01391-x]

"Ginkgolic acids (GA) are alkylphenol constituents of the leaves and fruits of Ginkgo biloba." [10.1038/s41598-020-61700-0]

"GA has shown pleiotropic effects in vitro, including: antitumor effects through inhibition of lipogenesis; decreased expression of invasion associated proteins through AMPK activation; and potential rescue of amyloid-β (Aβ) induced synaptic impairment." [10.1038/s41598-020-61700-0]

"GA has shown pleiotropic effects in vitro, including: antitumor effects through inhibition of lipogenesis; decreased expression of invasion associated proteins through AMPK activation; potential rescue of amyloid-β (Aβ) induced synaptic impairment; and inhibition of HIV protease activity as well as HIV viral replication^4–7." [10.1038/s41598-020-61700-0]

"GA was also reported to have activity against Escherichia coli and Staphylococcus aureus." [10.1038/s41598-020-61700-0]

"Several mechanisms for this activity have been suggested including: SUMOylation inhibition; blocking formation of the E1-SUMO intermediate; inhibition of fatty acid synthase; non-specific SIRT inhibition; and activation of protein phosphatase type-2C." [10.1038/s41598-020-61700-0]

"We report that GA inhibits human cytomegalovirus (HCMV) genome replication and Zika virus (ZIKV) infection of normal human astrocytes (NHA)." [10.1038/s41598-020-61700-0]

"We show a broad spectrum of fusion inhibition by GA of all three classes of fusion proteins including HIV, Ebola virus (EBOV), influenza A virus (IAV) and Epstein Barr virus (EBV)." [10.1038/s41598-020-61700-0]

"We show inhibition of a non-enveloped adenovirus." [10.1038/s41598-020-61700-0]

"Data showing inhibition of HSV-1 and CMV replication, when GA is administered post-infection, suggest a possible secondary mechanism targeting protein and DNA synthesis." [10.1038/s41598-020-61700-0]

"In light of the strong effect of GA on viral infection, even after the infection begins, it may potentially be used to treat acute infections (e.g. Coronavirus, EBOV, ZIKV, IAV and measles), and also topically for the successful treatment of active lesions (e.g. HSV-1, HSV-2 and varicella-zoster virus (VZV))." [10.1038/s41598-020-61700-0]

"Pair-wise Student t-tests were used to compare the outcome of a treatment as compared to the control." [10.1038/s41598-020-61700-0]

"For fusion experiments, Pair-wise Student t-tests were used to compare the outcome of a manipulation on fusion as compared to the control." [10.1038/s41598-020-61700-0]

"In light of the antiviral effect of GA on established viral infections of permissive cells, GA potentially could be used to treat acute viral infections (e.g. Coronavirus (COVID-19), EBOV, ZIKV, IAV and measles), and it might be determined to be useful in topical application for the successful treatment of active lesions (e.g. HSV-1, HSV-2 and VZV)." [10.1038/s41598-020-61700-0]

"As the outbreak of a deadly new coronavirus in China and its rapid spread is rattling countries, only the collective international experience and advances derived from past outbreaks can accelerate its control." [10.1038/s41591-020-0775-x]

"As the international community responds to an outbreak of coronavirus-induced pneumonia in Wuhan, China, early and open data sharing-which are vital for its control-depend on the trust that the data will not be used without proper attribution to those who generated it." [10.1038/s41564-020-0670-8]

"Follow World Health Organization advice, end secrecy in decision-making and cooperate globally." [10.1038/d41586-020-00772-4]

"The strengthening of the Chinese Center for Disease Control and Prevention has been a turning point in outbreak responses in the area." [10.1038/s41591-020-0771-1]

"This represents very welcome progress and development for global health security and diplomacy." [10.1038/s41591-020-0771-1]

"Despite COVID-19's spread to new countries, the evidence suggests it is yet possible to curb the virus." [10.1038/d41586-020-00623-2]

"As the new coronavirus continues its deadly spread, researchers must ensure that their work on this outbreak is shared rapidly and openly." [10.1038/d41586-020-00307-x]

"A compounding factor of the outbreak is the potential for the general public to misunderstand the facts and design conspiracy theories." [10.1038/s41591-020-0802-y]

"The emergence of a new coronavirus in China raises global alarm." [10.1038/s41579-020-0332-0]

"As the COVID-19 outbreak continues, the next pandemic could be prevented by ending the wildlife trade and reinvesting in the monitoring of potential zoonoses." [10.1038/s41559-020-1150-5]

"Biodiversity Research Center, Academia Sinica, Taipei, Taiwan." [10.1038/d41586-020-00693-2]

"Biology Institute, Federal Fluminense University, Niterói, Brazil." [10.1038/d41586-020-00782-2]

"National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland, USA." [10.1038/d41586-020-00694-1]

"University of the Chinese Academy of Sciences, Beijing, China." [10.1038/d41586-020-00522-6]

"Researchers are racing to find out more about the epidemiology and genetic sequence of the coronavirus spreading in Asia and beyond." [10.1038/d41586-020-00166-6]

"Experts weigh up the best-and worst-case scenarios as the World Health Organization declares a global health emergency." [10.1038/d41586-020-00236-9]

"As HIV drugs, stem cells and traditional Chinese medicines vie for a chance to prove their worth, the World Health Organization attempts to bring order to the search." [10.1038/d41586-020-00444-3]

"As cases in Washington state soar, virologists are working around the clock to diagnose cases, reveal routes of transmission and test treatments." [10.1038/d41586-020-00676-3]

"Mice originally bred for SARS research are in high demand." [10.1038/d41586-020-00698-x]

"The latest science news, in brief." [10.1038/d41586-020-00270-7]

"The latest science news, in brief." [10.1038/d41586-020-00589-1]

"The latest science news, in brief." [10.1038/d41586-020-00360-6]

"The latest science news, in brief." [10.1038/d41586-020-00752-8]

As scientific meetings are canceled worldwide, researchers are rethinking how they network-a move that some say is long overdue. [10.1038/d41586-020-00786-y]

"The latest science news, in brief." [10.1038/d41586-020-00453-2]

"Scientists need the pathogen to probe the biology of the emerging infection and to develop tests, drugs and vaccines." [10.1038/d41586-020-00262-7]

"Pangolins are a prime suspect, but a slew of genetic analyses has yet to find conclusive proof." [10.1038/d41586-020-00548-w]

"From laboratory closures to equipment shortages, researchers worldwide tell Nature how they have been affected by the epidemic." [10.1038/d41586-020-00478-7]

"The launch is on track for July, as Europe and Russia announce a two-year delay in their journey to the red planet." [10.1038/d41586-020-00739-5]

"Concerns are rising about the virus's potential to circulate undetected in Africa and Asia." [10.1038/d41586-020-00405-w]

"The latest science news, in brief." [10.1038/d41586-020-00670-9]

"Researchers have identified microscopic features that could make the pathogen more infectious than the SARS virus-and serve as drug targets." [10.1038/d41586-020-00660-x]

"From preparing for pandemics to boosting crop yields, Nigerian scientists who work and train abroad are making the world safer." [10.1038/d41586-020-00588-2]

"Structural biologist Rolf Hilgenfeld has been working on coronavirus treatments since the SARS outbreak." [10.1038/d41586-020-00190-6]